Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuebijing Injection for Sepsis
ChiCTR-IPR-17012713Phase 4Recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Oct 2017
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of xuebijing in sepsis (2 arms), sponsored by Zhongda Hospital, Southeast University. Primary endpoint: All-cause mortality. Started Oct 2017; status: recruiting.
02
Drugs
xuebijing
03
Conditions
sepsis
Beyond the preview
Go deeper on ChiCTR-IPR-17012713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012713.